Compare XWEL & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XWEL | GNPX |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.2M |
| IPO Year | N/A | 2018 |
| Metric | XWEL | GNPX |
|---|---|---|
| Price | $0.46 | $1.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.9K | ★ 311.5K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,523,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $1.71 |
| 52 Week High | $1.62 | $55.00 |
| Indicator | XWEL | GNPX |
|---|---|---|
| Relative Strength Index (RSI) | 19.01 | 37.42 |
| Support Level | $0.43 | $1.71 |
| Resistance Level | $0.48 | $2.03 |
| Average True Range (ATR) | 0.05 | 0.16 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 9.55 | 33.97 |
XWELL Inc is a health and wellness holding company. It is an airport retailer of spa services through XpresSpa locations, offering travelers premium spa services, including massage, nail, and skincare, as well as spa and travel products. It operates four reportable operating segments: XpresSpa. XpresTest, Naples Wax Center and Treat. XpresSpa provides travelers with premium spa services, including massage, nail and skin care, as well as spa and travel products. Treat is a travel health and wellness brand that offers in-airport spa. XpresTest provides COVID-19 screening and diagnostic testing in partnership with the CDC. Naples Wax Center operates three high-performing locations with core products and service offerings from face and body waxing to a range of skincare and cosmetic products.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.